| Vascular Biology |
| Molecular and Genomic Biology | Atherosclerosis and Vascular | Immunobiology of Disease Nitric Oxide Related Research | Progenitor Cell Therapeutics |
Molecular and Genomic Vascular Receptor Biology
The work in our laboratory is focused on four areas: Identification of novel factor(s) that may aid in protection of myocardium, understanding of signals involved in homing of bone marrow derived stem cells to the heart, control of rennin gene expression and gene therapy for cardiovascular diseases.
Project 1: We are developing a preventive gene therapy strategy for myocardial protection from future ischemia/reperfusion (I/R) injury involving a single administration of a therapeutic gene with a vector system capable of efficient and long-term myocyte specific and inducible expression of the therapeutic gene.
Project 3: We are investigating the mechanisms of protection by genetically modified MSCs. We hypothesize that MSCs overexpressing Akt can secrete paracrine factor(s), which can confer cytoprotection, reduce apoptosis and salvage myocardium. We are now in the process of identifying these factor(s) and demonstrating their therapeutic potential either alone or in combination and understanding the mechanism of cardiac protection and repair. In addition we are in the process of cloning several novel genes with secretory protein products identified from the microarray studies performed with MSCs.
Project 4: The goals of this project are to identify colocalization of a nuclear hormone receptor family member, LXR, and renin in vivo, understanding consequences of juxtaglomerular cell specific over expression and inhibition of LXR using genetically targeted mice and understanding the consequences of disruption of CNRE in the renin gene. These experiments will define the role of LXR in renin regulation.
Selected Publications
- Melo LG et.al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 2002 Feb 5;105(5):602-7.
- Mangi AA et.al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003 Sep;9(9):1195-201.
- Pachori AS et.al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12282-7.
- Gnecchi M. et.al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005 Apr;11(4):367-8.
-
Morello F. et.al. Liver X receptors a and ß regulate renin expression in vivo. J Clin Invest. 2005 Jul;115(7):1913-22.




DHTS WEB SERVICES